Sobi Loses Private Equity Buyout
An $8bn public-to-private takeout by two private equity firms of the Swedish rare disease specialist collapses because total tenders to the offer fell below a 90% threshold.
You may also be interested in...
The Swedish rare disease specialist has expanded its hematology franchise by getting the European rights to ADC Therapeutics’ Zynlonta, which has yet to make much impact commercially in the US.
Chinese firm RareStone licenses Rhythm’s Imcivree in greater China and will help enroll label-expansion studies for the drug. Omeros sells ophthalmic surgery drug Omidria and its commercial team to Rayner Surgical Group.
Apellis plans to file pegcetacoplan for approval as the first drug to treat the advanced AMD condition geographic atrophy, despite the C3 inhibitor hitting its endpoint in only one of two pivotal trials.